Skip to main content
. 2019 Apr 9;8(5):2514–2523. doi: 10.1002/cam4.2025

Table 1.

Baseline characteristics of patients with benign prostate hyperplasia compared between those with and without metformin treatment

Nonmetformin N = 2906 Metformin N = 2906 P‐value
Age, y 68.03 ± 8.67 66.41 ± 8.25 <0.0001
Age group <0.0001
50‐64 1048 (36.06) 1244 (42.81)
65‐79 1644 (56.57) 1554 (53.48)
≥80 214 (7.36) 108 (3.72)
TCM for DM 1220 (50.71) 1186 (49.29) 0.3652
TCM for BPH 1256 (50.65) 1224 (49.35) 0.3961
Insulin usage 66 (2.27) 520 (17.89) <0.0001
Severity of type 2 diabetes <0.0001
Low 1026 (35.31) 432 (14.87)
Midden 1026 (35.31) 2004 (68.96)
High 854 (29.39) 470 (16.17)
PSA (times/per year) 0.17 ± 0.32 0.18 ± 0.31 0.5999
Comorbidities
Myocardial infarction 42 (1.45) 46 (1.58) 0.6674
Congestive heart failure 122 (4.20) 138 (4.75) 0.3100
Peripheral vascular disease 36 (1.24) 38 (1.31) 0.8150
Cerebrovascular disease 492 (16.93) 430 (14.80) 0.0260
Dementia 58 (2.00) 50 (1.72) 0.4371
Chronic lung disease 246 (8.47) 230 (7.91) 0.4441
Connective tissue disease 28 (0.96) 28 (0.96) >0.9999
Ulcer 888 (30.56) 964 (33.17) 0.0324
Chronic liver disease 552 (19.00) 562 (19.34) 0.7389
Hemiplegia 54 (1.86) 40 (1.38) 0.1454
Moderate or severe kidney disease 158 (5.44) 176 (6.06) 0.3103
Tumor, leukemia, lymphoma 98 (3.37) 104 (3.58) 0.6674
Moderate or severe liver disease 8 (0.28) 4 (0.14) 0.2477
Malignant tumor, metastasis 0 (0.00) 18 (0.62)
AIDS 0 (0.00) 0 (0.00)
Retinopathy 54 (1.86) 52 (1.79) 0.8446
Nephropathy 42 (1.45) 40 (1.38) 0.8240
Neuropathy 88 (3.03) 72 (2.48) 0.1996
Erectile dysfunction 2750 (94.63) 2714 (93.39) 0.0466
Prostate cancer 94 (3.23) 72 (2.48) 0.0832

AIDS, acquired immune deficiency syndrome; BPH, benign prostate hyperplasia; DM, diabetes mellitus; PSA, prostate specific antigen; TCM, traditional Chinese medicine.